Meglife Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 04-01-2025
- Paid Up Capital ₹ 0.10 M
as on 04-01-2025
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 62.72%
(FY 2017)
- Profit 2.58%
(FY 2017)
- Ebitda 95.21%
(FY 2017)
- Net Worth 23.86%
(FY 2017)
- Total Assets 69.85%
(FY 2017)
About Meglife Pharmaceuticals
The Company is engaged in the Service Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Prince Jacob and Roseline Thomas serve as directors at the Company.
- CIN/LLPIN
U52310TN2011PTC079890
- Company No.
079890
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Meglife Pharmaceuticals Private Limited offer?
Meglife Pharmaceuticals Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Pantoprazole Drugs, Pantoprazole Tablets.
Who are the key members and board of directors at Meglife Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prince Jacob  | Director | 28-Mar-2011 | Current |
| Roseline Thomas | Director | 28-Mar-2011 | Current |
Financial Performance of Meglife Pharmaceuticals.
Meglife Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 62.72% increase. The company also saw a slight improvement in profitability, with a 2.58% increase in profit. The company's net worth Soared by an impressive increase of 23.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Meglife Pharmaceuticals?
In 2017, Meglife Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Meglife Pharmaceuticals?
Unlock and access historical data on people associated with Meglife Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meglife Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meglife Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
